• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受经皮冠状动脉介入治疗和双联抗血小板治疗的脑微出血患者的结局。

Outcomes of patients with cerebral microbleeds undergoing percutaneous coronary intervention and dual antiplatelet therapy.

机构信息

Department of Cardiovascular Medicine, Suita, Osaka, Japan.

Stroke and Cerebrovascular Disease, Suita, Osaka, Japan.

出版信息

Heart Vessels. 2024 Sep;39(9):763-770. doi: 10.1007/s00380-024-02404-7. Epub 2024 Apr 12.

DOI:10.1007/s00380-024-02404-7
PMID:38607378
Abstract

INTRODUCTION

Cerebral microbleeds (CMBs) on brain magnetic resonance imaging (MRI) are predictive of intracerebral hemorrhage (ICH). However, the risk of ICH in patients with CMBs who undergo percutaneous coronary intervention (PCI) while receiving dual antiplatelet therapy (DAPT) is unclear.

MATERIALS AND METHODS

We conducted a study on 329 consecutive patients with coronary artery disease who underwent PCI and were evaluated using a 3T MRI scanner. Based on T2*-weighted imaging, patients were classified into three groups: no CMBs, < 5 CMBs, or ≥ 5 CMBs. We determined the occurrence of ICH during follow-up.

RESULTS

At least 1 CMB was found in 109 (33%) patients. The mean number of CMBs per patient was 2.9 ± 3.6. Among the 109 patients with CMBs, 16 (15%) had ≥ 5 CMBs. Coronary stent implantation was performed in 321 patients (98%). DAPT was prescribed for 325 patients (99%). During a mean follow-up period of 2.3 years (interquartile range, 1.9-2.5 years), ICH occurred in one patient (1.1%) with four CMBs. There were no significant differences in the incidence of ICH (0% vs. 1.1% vs. 0%; p = 0.28). However, the rate of DAPT at 6 months of follow-up was significantly lower in patients with ≥ 5 CMBs than in patients with no CMBs or < 5 CMBs (89% vs. 91% vs. 66%, p = 0.026). Furthermore, there were no significant differences in systemic blood pressure during follow-up (123 ± 16 vs. 125 ± 16 vs. 118 ± 11 mmHg; p = 0.40).

CONCLUSION

Although a substantial number of patients who underwent PCI had cerebral microbleeds, at approximately two years of follow-up, intracerebral hemorrhage was very rare in our study population.

摘要

介绍

脑磁共振成像(MRI)上的脑微出血(CMB)可预测脑出血(ICH)。然而,在接受双联抗血小板治疗(DAPT)的同时接受经皮冠状动脉介入治疗(PCI)的 CMB 患者中发生 ICH 的风险尚不清楚。

材料和方法

我们对 329 例连续接受 PCI 治疗的冠心病患者进行了研究,并使用 3T MRI 扫描仪进行了评估。根据 T2*-加权成像,患者分为三组:无 CMB、<5 个 CMB 或≥5 个 CMB。我们确定了随访期间 ICH 的发生情况。

结果

109 例(33%)患者至少发现 1 个 CMB。每位患者的 CMB 平均数为 2.9±3.6。在 109 例有 CMB 的患者中,16 例(15%)有≥5 个 CMB。321 例患者(98%)植入了冠状动脉支架。325 例患者(99%)开具了 DAPT。在平均 2.3 年(四分位距 1.9-2.5 年)的随访期间,1 例(1.1%)有 4 个 CMB 的患者发生 ICH。ICH 的发生率无显著差异(0% vs. 1.1% vs. 0%;p=0.28)。然而,在 6 个月的随访中,≥5 个 CMB 的患者 DAPT 的使用率明显低于无 CMB 或<5 个 CMB 的患者(89% vs. 91% vs. 66%;p=0.026)。此外,随访期间的系统血压无显著差异(123±16 vs. 125±16 vs. 118±11 mmHg;p=0.40)。

结论

尽管接受 PCI 的患者中有相当数量的人存在脑微出血,但在我们的研究人群中,大约两年的随访期间,ICH 非常罕见。

相似文献

1
Outcomes of patients with cerebral microbleeds undergoing percutaneous coronary intervention and dual antiplatelet therapy.接受经皮冠状动脉介入治疗和双联抗血小板治疗的脑微出血患者的结局。
Heart Vessels. 2024 Sep;39(9):763-770. doi: 10.1007/s00380-024-02404-7. Epub 2024 Apr 12.
2
Prevalence and Risk Factors of Silent Cerebral Microbleeds in Patients with Coronary Artery Disease.冠心病患者无症状性脑微出血的患病率及相关危险因素。
J Stroke Cerebrovasc Dis. 2022 Jan;31(1):106211. doi: 10.1016/j.jstrokecerebrovasdis.2021.106211. Epub 2021 Nov 22.
3
Number of cerebral microbleeds after intracranial/extracranial stenting and dual antiplatelet therapy.颅内/外支架置入和双联抗血小板治疗后的脑微出血数量。
J Chin Med Assoc. 2022 Jun 1;85(6):704-708. doi: 10.1097/JCMA.0000000000000718. Epub 2022 Jun 10.
4
Antiplatelet therapy and future intracerebral hemorrhage in hemodialysis patients with cerebral microbleeds.抗血小板治疗与伴有脑微出血的血液透析患者的未来颅内出血。
J Clin Neurosci. 2021 Aug;90:155-160. doi: 10.1016/j.jocn.2021.05.068. Epub 2021 Jun 8.
5
Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy.非瓣膜性心房颤动患者行经皮冠状动脉介入治疗后发生卒中和脑出血的风险:比较双联与三联抗栓治疗的随机对照试验的系统评价和荟萃分析。
J Stroke Cerebrovasc Dis. 2021 Apr;30(4):105654. doi: 10.1016/j.jstrokecerebrovasdis.2021.105654. Epub 2021 Feb 10.
6
Dual antiplatelet therapy in acute ischaemic stroke with or without cerebral microbleeds.伴有或不伴有脑微出血的急性缺血性脑卒中的双联抗血小板治疗。
Eur J Neurosci. 2023 Apr;57(7):1197-1207. doi: 10.1111/ejn.15938. Epub 2023 Feb 23.
7
Risk of intracerebral hemorrhage in patients with cerebral microbleeds undergoing endovascular intervention.颅内微出血患者血管内介入治疗的脑出血风险。
Stroke. 2012 Jun;43(6):1532-6. doi: 10.1161/STROKEAHA.111.626853. Epub 2012 Apr 24.
8
Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial.新型血小板聚集功能检测指导下的稳定型冠状动脉疾病行经皮冠状动脉介入治疗患者的个体化抗血小板治疗:一项随机对照临床试验。
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):211-221. doi: 10.1093/ehjcvp/pvz059.
9
Determinants and Clinical Outcomes of Extended Dual Antiplatelet Therapy over 3 Years after Drug-Eluting Stent Implantation: A Retrospective Analysis.药物洗脱支架置入后 3 年以上延长双联抗血小板治疗的决定因素和临床结局:回顾性分析。
Yonsei Med J. 2020 Jul;61(7):597-605. doi: 10.3349/ymj.2020.61.7.597.
10
Correlation between antiplatelet therapy in secondary prevention of acute cerebral infarction and cerebral microbleeds: A susceptibility-weighted imaging (SWI) study.抗血小板治疗在急性脑梗死二级预防中的相关性与脑微出血:磁共振磁敏感加权成像(SWI)研究。
J Xray Sci Technol. 2018;26(4):623-633. doi: 10.3233/XST-17361.

本文引用的文献

1
Diagnostic ability of Japanese version of high bleeding risk criteria for ischemic outcomes in patients with acute myocardial infarction.日本版急性心肌梗死缺血性结局高出血风险标准的诊断能力。
Heart Vessels. 2024 Jan;39(1):1-9. doi: 10.1007/s00380-023-02303-3. Epub 2023 Aug 20.
2
Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT).慢性肾脏病患者急性冠状动脉综合征中双联抗血小板治疗的应用和结局:来自加拿大观察性抗血小板研究(COAPT)的见解。
Heart Vessels. 2022 Aug;37(8):1291-1298. doi: 10.1007/s00380-022-02029-8. Epub 2022 Jan 28.
3
CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022.
CVIT 专家共识文件:急性心肌梗死(AMI)直接经皮冠状动脉介入治疗(PCI)更新 2022 版
Cardiovasc Interv Ther. 2022 Jan;37(1):1-34. doi: 10.1007/s12928-021-00829-9. Epub 2022 Jan 12.
4
Prevalence and Risk Factors of Silent Cerebral Microbleeds in Patients with Coronary Artery Disease.冠心病患者无症状性脑微出血的患病率及相关危险因素。
J Stroke Cerebrovasc Dis. 2022 Jan;31(1):106211. doi: 10.1016/j.jstrokecerebrovasdis.2021.106211. Epub 2021 Nov 22.
5
JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease.《日本循环学会(JCS)2020年冠状动脉疾病患者抗栓治疗指南重点更新》
Circ J. 2020 Apr 24;84(5):831-865. doi: 10.1253/circj.CJ-19-1109. Epub 2020 Mar 13.
6
Comparison of Long-Term Mortality in Patients With Previous Coronary Artery Bypass Grafting Who Underwent Percutaneous Coronary Intervention With Versus Without Optimal Medical Therapy.接受经皮冠状动脉介入治疗的既往冠状动脉旁路移植术患者长期死亡率的比较:有或无最佳药物治疗的情况
Am J Cardiol. 2018 Jul 15;122(2):206-212. doi: 10.1016/j.amjcard.2018.04.009. Epub 2018 Apr 12.
7
Long-Term Prognostic Implications of Cerebral Microbleeds in Chinese Patients With Ischemic Stroke.中国缺血性脑卒中患者脑微出血的长期预后意义。
J Am Heart Assoc. 2017 Dec 7;6(12):e007360. doi: 10.1161/JAHA.117.007360.
8
Anticoagulation combined with antiplatelet therapy in patients with left ventricular thrombus after first acute myocardial infarction.急性心肌梗死后首次发生左心室血栓患者的抗凝联合抗血小板治疗。
Eur Heart J. 2018 Jan 14;39(3):201-208. doi: 10.1093/eurheartj/ehx551.
9
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).2017年欧洲心脏病学会(ESC)与欧洲心胸外科学会(EACTS)合作制定的冠状动脉疾病双联抗血小板治疗重点更新:欧洲心脏病学会(ESC)和欧洲心胸外科学会(EACTS)冠状动脉疾病双联抗血小板治疗特别工作组。
Eur Heart J. 2018 Jan 14;39(3):213-260. doi: 10.1093/eurheartj/ehx419.
10
Cerebral Microbleeds as Predictors of Mortality: The Framingham Heart Study.脑微出血作为死亡率的预测指标:弗雷明汉心脏研究
Stroke. 2017 Mar;48(3):781-783. doi: 10.1161/STROKEAHA.116.015354. Epub 2017 Jan 31.